En undersøgelse, der evaluerer sikkerheden og effektiviteten af kombinationer af flere behandlinger hos deltagere med myelomatose (PLYCOM)
En platformsundersøgelse, der evaluerer sikkerheden og effektiviteten af kombinationer af flere behandlinger hos patienter med myelomatose
CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Cevos + Len substudy(SS) 2 (DIRAC):
This substudy will explore the combination of cevostamab and lenalidomide as post-transplant maintenance therapy in participants with MM with high-risk cytogenetic features who experienced at least a partial response (PR) after induction.
Cevostamab + Iberdomide SS4 (CHAWLA):
This substudy will evaluate the safety, tolerability, PK, and pharmacodynamics of the combination of cevostamab and iberdomide in participants with R/R MM who have received at least three prior lines of therapy, including a PI, an IMiD, and an anti-CD38 monoclonal antibody.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Undersøgelse Kontakt Backup
- Navn: Reference Study ID Number: CO43923 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S. and Canada)
- E-mail: global-roche-genentech-trials@gene.com
Studiesteder
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Rekruttering
- Prince of Wales Hospital
-
-
Victoria
-
Fitzroy, Victoria, Australien, 3065
- Rekruttering
- St Vincent's Hospital Melbourne
-
-
-
-
-
Pierre-Bénite, Frankrig, 69310
- Rekruttering
- CHU Lyon Sud - Service Hématologie
-
Toulouse, Frankrig, 31059
- Rekruttering
- IUCT Oncopole
-
Tours, Frankrig, 37044
- Rekruttering
- Hopital Bretonneau
-
Villejuif, Frankrig, 94800
- Trukket tilbage
- IGR
-
-
-
-
-
Gda?sk, Polen, 80-214
- Rekruttering
- Uniwersyteckie Centrum Kliniczne
-
Olsztyn, Polen, 10-228
- Rekruttering
- Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
-
Późna, Polen, 60-569
- Trukket tilbage
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
-
-
-
-
Madrid, Spanien, 28040
- Rekruttering
- Fundacion Jimenez Diaz
-
Valencia, Spanien, 46010
- Rekruttering
- Hospital Clinico Universitario de Valencia
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08915
- Rekruttering
- Hospital Universitari Germans Trias i Pujol
-
-
-
-
-
Seoul, Sydkorea, 03722
- Rekruttering
- Severance Hospital, Yonsei University Health System
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center
-
-
-
-
-
Hamburg, Tyskland, 20246
- Rekruttering
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
-
Leipzig, Tyskland, 04103
- Rekruttering
- Universitätsklinikum Leipzig - Klinik und Poliklinik für Hämatologie
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosed with MM per International Myeloma Working Group (IMWG) criteria
- Eastern Cooperative Oncology Group Performance Status of 0, or 1, or 2
- Resolution of AEs from prior anti-cancer therapy to Grade <=1
- Agreement to undergo scheduled assessments and procedures
Additional Inclusion Criteria for SS2:
- Completion of planned induction therapy and achievement of at least a partial response (PR)
- Autologous Stem Cell Transplant (SCT) within 100 days prior to first study treatment and the absence of progressive disease
- Cytogenetic high-risk features at diagnosis
- Treatment with any investigational medicinal products, systemic cancer therapies, immunotherapies received previously in CO43923 (any arms) within 5 half-lives or 3 weeks whichever is the shortest
- Agreement to comply with all local requirements of the lenalidomide risk minimization plan, which includes the global pregnancy prevention program
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception
- For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom even if they have had a prior vasectomy, and agreement to refrain from donating sperm
Additional Inclusion Criteria for SS4:
- Previously exposed to at least a PI, an IMiD, and an anti-CD38 antibody for the treatment of R/R MM for whom no suitable SOC therapy options are available
Exclusion Criteria:
- Inability to comply with protocol-mandated hospitalization and procedures
- History of confirmed progressive multifocal leukoencephalopathy
- History of other malignancy within 2 years prior to screening
- Current or past history of central nervous system (CNS) disease
- Significant cardiovascular disease that may limit a participant's ability to adequately respond to a CRS event
- Symptomatic active pulmonary disease or requiring supplemental oxygen
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection requiring treatment with IV antibiotics where the last dose of IV antibiotics was given within 14 days prior to first study treatment
- Known or suspected chronic active Epstein-Barr virus (EBV) infection
- Positive serologic or PCR test results for acute or chronic hepatitis B virus (HBV) infection
- Acute or chronic hepatitis C virus (HCV) infection
- Known history of HIV seropositivity
- Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study
- Any medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
Additional Exclusion Criteria for SS2:
- Hypersensitivity reactions to lenalidomide or other immunomodulatory drugs
- Harbor lesions at proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
- Prior treatment with any investigational medicinal product, systemic cancer therapy, or immunotherapies in any arm of study CO43923 within 5 half-lives or 3 weeks, whichever is shorter
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antimicrobials where the last dose of IV antimicrobial was given within 14 days prior to first study treatment
- History of erythema multiforme, Grade >=3 rash, or blistering following prior treatment with immunomodulatory derivatives
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment Exlcusion Criteria Applicable to SS2 and SS4
- History of autoimmune disease
- Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within the 14-day period before the first dose of the study drug (does not include pretreatment medication)
- Active symptomatic COVID-19 infection at study enrollment or requiring treatment with IV antiviral where the last dose of IV antiviral treatment was given within 14 days prior to first study treatment. Participants with active COVID-19 infection must have clinical recovery and two negative antigen tests at least 24 hours apart prior to first study treatment.
- Positive and quantifiable EBV PCR or CMV PCR prior to first study treatment
Additional Exclusion Criteria for SS4:
- Treatment with any investigational medicinal products, systemic cancer therapies, immunotherapies within 5 half-lives or 12 weeks before starting pre-phase
- History of anaphylaxis or hypersensitivity, including >=Grade 3 rash, during prior treatment with IMiDs, dexamethasone, any CELMoDs, or the excipients contained in the formulations
- Known anaphylaxis, allergies, hypersensitivity, or intolerance to boron or mannitol, hyaluronidase, sorbitol, corticosteroids, monoclonal antibodies (or recombinant antibody-related fusion proteins), or human proteins, CRBN modulating agents or their excipients, or known sensitivity to mammalian-derived products
- Administration of strong CYP3A modulators; administration of proton-pump inhibitors within 2 weeks of starting study treatment
- Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
- Concurrent administration of a strong inhibitor, modulator or inducer of cytochrome P450 (CYP3A4/5) (including within 14 days of initiating study treatment)
- History of malignancies, other than MM, unless the subject has been free of the disease for >=5 years
- Peripheral neuropathy >Grade 2
- Prior treatment with cevostamab or another agent targeting FcRH5 or iberdomide
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment
- History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug rash with eosinophilia and systemic symptoms
- Treatment with systemic immunosuppressive medications
- Prior treatment with CAR T-cell therapy (autologous or allogeneic) within 12 weeks before starting pre-phase
- Autologous SCT within 100 days prior to starting pre-phase
- Prior allogeneic SCT
- Plasmacytoma in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Substudy 2: Dose Escalation and Expansion
In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on Day(D)1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 and D15 for cycles 1-6 and D1 of cycle 7 onwards. Each cycle is 28 days. Lenalidomide will be administered by mouth (PO) on a 28-day cycle. During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Lenalidomide will be administered PO on a 28-day cycle. Enrollment for Substudy 2 has closed. |
Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles. Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles. Lenalidomide will be administered PO on days 1-21 of a 28-day cycle. Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary. |
|
Eksperimentel: Substudy 4: Dose Escalation and Expansion
In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on D1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 of each cycle, every 3 weeks (Q3W). Each cycle is 21 days. Iberdomide will be administered PO on a 21-day cycle. During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Iberdomide will be administered PO on a 21-day cycle. |
Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles. Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles. Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary. Iberdomide will be administered PO on days 1-14 of a 21-day cycle. Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Fase 1: Procentdel af deltagere med uønskede hændelser (AE'er)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Fase 2: Objektiv responsrate (ORR)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 2: Komplet respons (CR) eller stringent komplet respons (sCR) rate
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Fase 2: Rate of Very Good Partial Response (VGPR) eller bedre
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 2: Progressionsfri overlevelse (PFS)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Fase 2: Samlet overlevelse (OS)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Fase 1: Konvertering til en bedre respons
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1: PFS
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Varighed af respons (DOR)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1: OS
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Minimal Residual Disease (MRD) Negativitetsrate
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1: ORR
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1: CR eller sCR Rate
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1: Sats for VGPR eller bedre
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 2: Trin 1: Procentdel af deltagere med AE'er
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Tid til første svar (for deltagere, der opnår et svar på PR eller bedre)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Tid til bedste respons (for deltagere, der opnår et svar på PR eller bedre)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Maksimal observeret koncentration (Cmax)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Minimum koncentration under steady-state betingelser inden for et doseringsinterval (Cmin)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Tid til maksimal koncentration (Tmax)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Areal under koncentration-tidskurven (AUC)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Total clearance af lægemiddel (CL)
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Distributionsvolumen ved stabil tilstand
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
|
Trin 1 og 2: Terminal halveringstid
Tidsramme: Baseline op til cirka 5 år
|
Baseline op til cirka 5 år
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Hemiske og lymfatiske sygdomme
- Myelomatose
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Carboxylsyrer
- Polycykliske forbindelser
- Piperidiner
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Steroider, fluoreret
- Gravideretrioler
- Phthalimider
- Phthalinsyrer
- Syrer, carbocykliske
- Piperidones
- Isoindoler
- Lenalidomid
- Dexamethason
- tocilizumab
- IberDomide
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CO43923
- 2021-005918-34 (EudraCT nummer)
- 2023 (U.S. NIH-bevilling/kontrakt)
- 2023-504484-16-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .